Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: past, present and future
- PMID: 11757788
Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: past, present and future
Abstract
Inflammation has been increasingly recognized as a major factor in the pathogenesis of cystic fibrosis (CF) lung disease. The use of anti-inflammatory medications to slow pulmonary deterioration has been the focus of much research over the past two decades. Oral corticosteroids are effective, but are associated with significant adverse effects when used long-term. Inhaled corticosteroids are being studied as an alternative to systemic steroids. High-dose ibuprofen has also been shown to be of benefit in CF patients but has not been widely used. A variety of other non-specific anti-inflammatory agents, as well as antioxidants and antiproteinases, have been evaluated or are currently under investigation for use in CF. At present, the anti-inflammatory therapies used to treat CF lung disease are limited. There is hope that agents being evaluated in ongoing clinical trials will prove more effective than those already tested and that future research will provide additional anti-inflammatory therapies for CF airway disease.
Similar articles
-
Treatment of airway inflammation in cystic fibrosis.Curr Opin Pulm Med. 1996 Nov;2(6):452-6. Curr Opin Pulm Med. 1996. PMID: 9363184 Review.
-
Anti-inflammatory therapy in cystic fibrosis.J Cyst Fibros. 2005 Aug;4 Suppl 2:45-8. doi: 10.1016/j.jcf.2005.05.010. J Cyst Fibros. 2005. PMID: 16005266 Review.
-
Ibuprofen therapy for cystic fibrosis lung disease: revisited.Curr Opin Pulm Med. 2008 Nov;14(6):567-73. doi: 10.1097/MCP.0b013e32831311e8. Curr Opin Pulm Med. 2008. PMID: 18812834 Review.
-
Emerging therapies in cystic fibrosis.Ther Adv Respir Dis. 2010 Jun;4(3):177-85. doi: 10.1177/1753465810371107. Ther Adv Respir Dis. 2010. PMID: 20530065 Review.
-
[Treatment of airway inflammation in cystic fibrosis].Arch Pediatr. 2007 Nov;14(11):1350-5. doi: 10.1016/j.arcped.2007.06.029. Epub 2007 Aug 15. Arch Pediatr. 2007. PMID: 17702549 Review. French.
Cited by
-
Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.Eur J Clin Pharmacol. 2012 May;68(5):479-503. doi: 10.1007/s00228-011-1161-x. Epub 2011 Nov 22. Eur J Clin Pharmacol. 2012. PMID: 22105373 Review.
-
Antioxidant supplementation for lung disease in cystic fibrosis.Cochrane Database Syst Rev. 2019 Oct 3;10(10):CD007020. doi: 10.1002/14651858.CD007020.pub4. Cochrane Database Syst Rev. 2019. PMID: 31580490 Free PMC article. Review.
-
High-dose ibuprofen therapy associated with esophageal ulceration after pneumonectomy in a patient with cystic fibrosis: a case report.BMC Pediatr. 2004 Sep 13;4:19. doi: 10.1186/1471-2431-4-19. BMC Pediatr. 2004. PMID: 15363106 Free PMC article. Review.
-
A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patients.BMC Pediatr. 2006 May 24;6:17. doi: 10.1186/1471-2431-6-17. BMC Pediatr. 2006. PMID: 16719931 Free PMC article. Clinical Trial.
-
Neutrophil elastase enhances sputum solubilization in cystic fibrosis patients receiving DNase therapy.PLoS One. 2011;6(12):e28526. doi: 10.1371/journal.pone.0028526. Epub 2011 Dec 9. PLoS One. 2011. PMID: 22174830 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous